MX2008001645A - Composiciones de fexofendina en suspension farmaceutica oral. - Google Patents
Composiciones de fexofendina en suspension farmaceutica oral.Info
- Publication number
- MX2008001645A MX2008001645A MX2008001645A MX2008001645A MX2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A MX 2008001645 A MX2008001645 A MX 2008001645A
- Authority
- MX
- Mexico
- Prior art keywords
- fexofenadine
- pharmaceutical suspension
- oral pharmaceutical
- suspension compositions
- oral
- Prior art date
Links
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title abstract 12
- 229960003592 fexofenadine Drugs 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000007971 pharmaceutical suspension Substances 0.000 title abstract 3
- 229940008201 allegra Drugs 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- -1 'Allegra?? Chemical compound 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion de fexofenadina en suspension farmaceutia oral. La fexofenadina es una mezcla de fexofenadina compactada y fexofenadina simple en una relacion de 0.01: 0.99 a 0.99 a 0.01 con un tamano de particula medio de las particulas de fexofenadina en el intervalo de 10( a 250(. Una composicion de fexofenadina en suspension farmaceutica oral, que es bioequivalente a una forma farmaceutica en tableta de fexofenadina comercializada con el nombre comercial Allegra(r). La bioequivalencia entre una formulacion en suspension y la formulacion comercial en forma de tableta de fexofenadina, es decir, `Allegra(r)??, se logra mediante el uso de una mezcla de fexofenadina compactada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN703KO2005 | 2005-08-05 | ||
| PCT/IN2006/000277 WO2007017905A1 (en) | 2005-08-05 | 2006-08-03 | Oral pharmaceutical suspension compositions of fexofenadine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008001645A true MX2008001645A (es) | 2008-04-07 |
Family
ID=37529426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008001645A MX2008001645A (es) | 2005-08-05 | 2006-08-03 | Composiciones de fexofendina en suspension farmaceutica oral. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080274196A1 (es) |
| JP (1) | JP5133244B2 (es) |
| BR (1) | BRPI0614231A2 (es) |
| MX (1) | MX2008001645A (es) |
| WO (1) | WO2007017905A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000274A (es) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | Formulación de suspensión de fexofenadina |
| FR2911506B1 (fr) * | 2007-01-18 | 2009-07-03 | Ceva Sante Animale Sa | Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees |
| US8999395B2 (en) | 2007-02-09 | 2015-04-07 | Ceva Sante Animale | Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions |
| AR094761A1 (es) * | 2013-02-14 | 2015-08-26 | Sanofi Sa | Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma |
| WO2014124981A1 (en) | 2013-02-14 | 2014-08-21 | Sanofi | Chewable composition for oral administration and process for preparing thereof |
| US10130620B2 (en) | 2013-07-01 | 2018-11-20 | Aventisub Llc | Liquid pharmaceutical composition for oral administration comprising fexofenadine |
| CN107536804A (zh) * | 2016-06-28 | 2018-01-05 | 浙江普利药业有限公司 | 盐酸非索非那定干混悬剂及其制备方法 |
| EP3668508A1 (en) * | 2017-08-19 | 2020-06-24 | FTF Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
| US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US11446243B1 (en) * | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| JP7546138B2 (ja) * | 2021-12-21 | 2024-09-05 | 上海奥全生物医葯科技有限公司 | 固形剤形を水に分散させて懸濁液を形成する方法、懸濁液および固体剤形を投与する方法 |
| CN115715759B (zh) * | 2022-11-03 | 2024-01-12 | 京海盛达(北京)科技有限公司 | 一种抗组胺混悬剂及其制备方法 |
| AU2023424246A1 (en) * | 2023-01-20 | 2025-01-09 | Opella Healthcare Group Sas | Paraben-free fexofenadine formulations |
| CN118286163B (zh) * | 2024-04-03 | 2025-07-15 | 桂林华信制药有限公司 | 一种盐酸非索非那定干混悬剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US6451815B1 (en) * | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| WO2004066974A1 (en) * | 2003-01-30 | 2004-08-12 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| GB0319935D0 (en) * | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
-
2006
- 2006-08-03 BR BRPI0614231-1A patent/BRPI0614231A2/pt not_active IP Right Cessation
- 2006-08-03 US US11/997,954 patent/US20080274196A1/en not_active Abandoned
- 2006-08-03 MX MX2008001645A patent/MX2008001645A/es unknown
- 2006-08-03 JP JP2008524680A patent/JP5133244B2/ja not_active Expired - Fee Related
- 2006-08-03 WO PCT/IN2006/000277 patent/WO2007017905A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20080274196A1 (en) | 2008-11-06 |
| JP5133244B2 (ja) | 2013-01-30 |
| JP2009503058A (ja) | 2009-01-29 |
| WO2007017905A1 (en) | 2007-02-15 |
| BRPI0614231A2 (pt) | 2012-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008001645A (es) | Composiciones de fexofendina en suspension farmaceutica oral. | |
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| WO2007016563A3 (en) | Alcohol resistant pharmaceutical formulations | |
| MX2010008234A (es) | Nueva dosificacion y formulacion. | |
| DE60231298D1 (de) | Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen | |
| IS7142A (is) | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi | |
| WO2007143155A3 (en) | Sustained release pharmaceutical dosage form containing phenylephrine | |
| MY177027A (en) | Novel dosage and formulation | |
| EA200600479A1 (ru) | Фармацевтический состав, включающий соединения лантана | |
| MY144477A (en) | Galenic formulations of organic compounds | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| WO2007112272A3 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| CA2535013A1 (en) | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| ATE533476T1 (de) | Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür | |
| WO2008062475A3 (en) | Pharmaceutical compositions of ursodiol | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| ATE488225T1 (de) | Kaubare, lutschbare und verschluckbare tablette mit einer calciumhaltigen verbindung als wirkstoff | |
| MY177591A (en) | Nk1 receptor antagonist composition | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| PL382307A1 (pl) | Sposób przygotowania farmaceutycznej kompozycji w postaci szybko dyspersyjnej dawki i stała, doustna, szybko dyspersyjna postać dawki | |
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| WO2007120838A3 (en) | Rapidly disintegrating solid oral dosage form of liquid dispersions | |
| WO2006096194A3 (en) | Drinkable immediate release tablet made with direct compression of memantine or neramexane |